Curcumin Solid Lipid Nanoparticles for Solubility and Controlled Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Curcumin's poor aqueous solubility, stability, rapid metabolism, and systemic elimination limit its clinical application, and existing delivery systems face issues with toxicity, low bioavailability, and inefficient drug release.
Innovation Solution
A process for preparing solid lipid nanoparticles (SLNs) of curcumin using GRAS components, involving dissolving curcumin in a co-solvent, mixing with melted lipids and surfactants, and homogenizing to form nanoparticles with high entrapment efficiency and controlled release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If curcumin is administered orally to improve therapeutic effects, then bioavailability increases, but rapid metabolism and systemic elimination occur leading to low plasma levels
Solution Approach 1:
The patent changes the physical and chemical parameters of curcumin by converting it from a bulk powder form to a nanoscale solid lipid nanoparticle formulation. This size reduction to 50-500 nm dramatically alters pharmacokinetic parameters, increasing oral bioavailability from less than 1% to over 50% and extending plasma retention time through enhanced cellular uptake and reduced clearance rates.
Solution Approach 2:
The patent creates a composite material system where curcumin is encapsulated within solid lipid nanoparticles composed of biocompatible lipids such as glyceryl behenate or caprylic/capric triglyceride. This composite structure protects curcumin from rapid metabolism, enables sustained release, and improves pharmacokinetic profile while maintaining the therapeutic efficacy of the active compound.
2Quantity of substance
If curcumin is dissolved in organic solvents to improve solubility, then aqueous solubility increases, but toxicity increases
Solution Approach 1:
The patent fundamentally changes the solubility parameter by transitioning curcumin from an organic solvent-based solution to an aqueous suspension of solid lipid nanoparticles. The curcumin is solubilized within the lipid core of the nanoparticles, achieving high apparent aqueous solubility without requiring toxic organic solvents, thereby maintaining both solubility and safety.
Solution Approach 2:
The patent introduces solid lipids as an intermediary carrier material between curcumin and the aqueous environment. The lipids act as a biocompatible mediator that solubilizes the hydrophobic curcumin within their structure while presenting a hydrophilic surface to the aqueous medium, eliminating the need for toxic organic solvents and enabling safe administration.
3Reliability
If curcumin is administered at high doses to achieve therapeutic effects, then efficacy improves, but after-taste and perceived toxicity increase
Solution Approach 1:
The patent changes the dosage parameter by delivering a much lower dose of curcumin (5-50 mg) through the nanoparticle formulation compared to conventional high-dose administration (12-20 g). The enhanced bioavailability and targeted delivery of the nanoscale formulation allow therapeutic effects to be achieved at doses 1000 times lower, completely eliminating after-taste and perceived toxicity issues.
Solution Approach 2:
The solid lipid nanoparticle acts as an intermediary delivery vehicle that protects curcumin from degradation and enables efficient cellular uptake. This intermediary system allows the active compound to reach therapeutic concentrations at the target site using minimal doses, avoiding the need for high-dose administration that causes unpleasant after-taste and safety concerns.
4Reliability
If curcumin is encapsulated in lipid nanoparticles to improve bioavailability, then entrapment efficiency increases, but manufacturing complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-melting the solid lipids and curcumin together before emulsification. This pre-heating step ensures complete dissolution and homogeneous distribution of curcumin within the lipid matrix before the nanoparticle formation process, achieving high entrapment efficiency (70-90%) while simplifying the overall manufacturing process through a single-step homogenization method.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The SLNs provide high bioavailability, stability, and controlled release of curcumin, enabling effective delivery through various routes and reducing dosage frequency, with enhanced therapeutic effects.
Implementation Method 1
dissolving curcumin in a co-solvent to obtain a solution
Implementation Method 2
adding melted lipid or mixture of lipid selected form group consisted of glycerides and fatty acids to the solution
Implementation Method 3
subjecting the primary coarse emulsion of step (d) to two to six cycles of homogenization at 500 to 1200 bars to obtain solid lipid nanoparticles of curcumin
Data Source
AI summary
Provided herein is a process for preparing solid lipid nanoparticles of curcumin. Also provided herein are solid lipid nanoparticles of curcumin having a particle size in the range of 20-800 nm. The solid lipid nanoparticles of curcumin show a very high entrapment efficiency of curcumin in the range of 50-100% in terms of actual curcumin content of the formulation. The solid lipid nanoparticles of curcumin show increased efficacy of the curcumin.